ASCO 2023 | What is the current state of genomic testing in metastatic colorectal cancer?

Jennifer Rachel Eads, MD, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, describes the present role of molecular testing in patients with newly diagnosed colorectal cancer. Whilst testing is predominantly conducted in patients with metastatic colorectal cancer, testing in earlier stages is beneficial to elucidate the microsatellite instability status of patients. Dr Eads additionally highlights HER2 as an emerging target and, thus, the need for HER2 biomarker testing. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.